Synapse - Matthew Hellmann

Search Within

Matthew David Hellmann

Results (411)

Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab

Journal Article

Topp, B. G.; Thiagarajan, K.; De Alwis, D. P.; Snyder, A.; Hellmann, M. D.
Annals of Oncology (2021)

Aligning tumor mutational burden (TMB) quantification across diagnostic platforms: Phase II of the Friends of Cancer Research TMB Harmonization Project

Journal Article

Vega, D. M.; Yee, L. M.; McShane, L. M.; Williams, P. M.; Chen, L.; Vilimas, T.; Fabrizio, D.; Funari, V.; Newberg, J.; Bruce, L. K.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer

Journal Article

Schoenfeld, A. J.; Antonia, S. J.; Awad, M. M.; Felip, E.; Gainor, J.; Gettinger, S. N.; Hodi, F. S.; Johnson, M. L.; Leighl, N. B.; Lovly, C. M.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial

Meeting Abstract

Peters, S.; Rizvi, N. A.; Kuziora, M.; Lai, Z.; Shrestha, Y.; Dey, A.; Barrett, J. C.; Scheuring, U.; Poole, L.; Abbosh, C.; more...
Annals of Oncology (2021)

Fulltext@MSK | Save

Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child

Journal Article

Ogishi, M.; Yang, R.; Aytekin, C.; Langlais, D.; Bourgey, M.; Khan, T.; Al Ali, F.; Rahman, M.; Delmonte, O. M.; Chrabieh, M.; more...
Nature Medicine (2021)

Fulltext@MSK | Save

Beyond steroids: Immunosuppressants in steroid-refractory or resistant immune-related adverse events

Journal Article

Luo, J.; Beattie, J. A.; Fuentes, P.; Rizvi, H.; Egger, J. V.; Kern, J. A.; Leung, D. Y. M.; Lacouture, M. E.; Kris, M. G.; Gambarin, M.; more...
Journal of Thoracic Oncology (2021)

Fulltext@MSK | Save

Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer

Journal Article

Castellanos, S. H.; Pagano, A.; Plodkowski, A. J.; Girshman, J.; Hellmann, M. D.; Rizvi, H.; Flynn, J.; Zheng, J.; Capanu, M.; Halpenny, D. F.; more...
Lung Cancer (2021)

Fulltext@MSK | Save

Immunotherapy-mediated thyroid dysfunction: Genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer

Journal Article

Luo, J.; Martucci, V. L.; Quandt, Z.; Groha, S.; Murray, M. H.; Lovly, C. M.; Rizvi, H.; Egger, J. V.; Plodkowski, A. J.; Abu-Akeel, M.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

An SU2C-Mark Foundation Lung collaborative update: Integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance

Meeting Abstract

Arniella, M. B.; Ravi, A.; Gainor, J.; Stewart, C.; Freeman, S.; Awad, M.; Forde, P.; Anagnostou, V.; Henick, B.; Riess, J. W.; more...
Cancer Research (2021)

Fulltext@MSK | Save

The development of an in vivo model of checkpoint acquired resistance, reveals a program of interferon hyperstimulation, resulting in dysregulation of MHC class I, protein translation/trafficking, and other unique pathways, that may be useful for guiding clinical strategy in patients with phenotypic similarities

Meeting Abstract

Fromm, G. J.; Memon, D.; de Silva, S.; Yoo, K. J.; Johannes, K.; Shuptrine, C.; Miriyala, J.; Patel, A.; Rangwala, F.; Opheim, Z.; more...
Cancer Research (2021)

Fulltext@MSK | Save